During the past decade, Institute of Clinical Oncology conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 5 clinical trials were completed, i.e. on average, 29.4% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 4 clinical trials were completed. i.e. 57.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institute of Clinical Oncology" #1 sponsor was "Helsinn Healthcare SA" with 2 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Queen Mary University of London" with 2 trials sponsored, "Biocad" with 1 trials sponsored and "Bioven Europe" with 1 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 14 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institute of Clinical Oncology" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "Cancer Research UK" with 1 trials as a collaborator, "GORTEC (Head and Neck Oncology and Radiotherapy Group)" with 1 trials as a collaborator, "George Clinical Pty Ltd" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Institute of Clinical Oncology" are "Breast Cancer" (3 trials), "Non-small Cell Lung Cancer" (2 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Cervical Cancer" (1 trials) and "Chemotherapy-Induced Nausea and Vomiting" (1 trials). Many other conditions were trialed in "Institute of Clinical Oncology" in a lesser frequency.

Most popular intervention types in "Institute of Clinical Oncology" are "Drug" (16 trials), "Biological" (3 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (6 trials), "Placebo" (6 trials), "Carboplatin" (3 trials), "Bevacizumab" (2 trials) and "Cisplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Institute of Clinical Oncology" are 11 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are NaN active trials in "Institute of Clinical Oncology". undefined are not yet recruiting, 5 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Institute of Clinical Oncology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institute of Clinical Oncology, 1 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Institute of Clinical Oncology has several departments that took part in Clinical trials: "Scientific Research National Center of Dermatology and Venereology LLC" - 2 trials, "Hepatology Clinic Hepa" - 2 trials